Baricitinib

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Baricitinib is a JAK (Janus Kinase) inhibitor and immunomodulatory drug currently FDA approved for Rheumatoid Arthritis, Alopecia Areata, and acute COVID-19. It is slated for a series of clinical trials for Long COVID run by Wes Ely funded by the NIH. [1]

  1. ↑ Fairbank, Rachel (April 2, 2024). "Long COVID still has no cure — so these patients are turning to research". Nature. 628 (8006): 26–28. doi:10.1038/d41586-024-00901-3.

immunomodulator An immunomodulator is a substance that affects the functioning of the immune system

See National Institutes of Health.

National Institutes of Health (NIH) - A set of biomedical research institutes operated by the U.S. government, under the auspices of the Department of Health and Human Services.

Retrieved from "https://me-pedia.org/w/index.php?title=Baricitinib&oldid=242706"